Entia Biosciences, Inc. (ERGO)

OTCMKTS · Delayed Price · Currency is USD
0.0403
0.00 (0.00%)
At close: Mar 2, 2026
40,200%
Market Cap 1.37M
Revenue (ttm) 265.47K
Net Income (ttm) -1.40M
Shares Out 34.06M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Average Volume 15,776
Open 0.0403
Previous Close n/a
Day's Range 0.0403 - 0.0403
52-Week Range 0.0001 - 0.0403
Beta 26.12
RSI 92.22
Earnings Date n/a

About Entia Biosciences

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceutical... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol ERGO
Full Company Profile

Financial Performance

In 2016, Entia Biosciences's revenue was $265,466, a decrease of -23.48% compared to the previous year's $346,910. Losses were -$1.40 million, -38.24% less than in 2015.

Financial Statements

News

There is no news available yet.